|
|
 |
|
Viewing report
|
|
|
|
Company Financials: Progenics Pharmaceuticals, Inc.
Datamonitor, Jan 2010
The Company Financials offers insights into the financial performance of the company over last five years for about 1000 leading global companies. The datapack covers wealth of financial information relating to income statement, balance sheet, and cash flow statements. .
Scope
- Contains five years data on income statement, balance sheet, cash flows and other financials in the reported currency and its US Dollar translation
- Provides key ratios
- Includes information on revenue distribution by business segments and geographies
Highlights of this title
Progenics Pharmaceuticals (Progenics) is a biopharmaceutical company engaged in the development and commercialization of therapeutic products to meet the medical needs in the areas of supportive care, virology and oncology.
Progenics is developing Relistor (methylnaltrexone bromide) for the treatment of opioid-induced side effects. Relistor is currently approved in over 30 countries. The company primarily operates in the US.
Key reasons to purchase this title
- Includes information on revenue distribution by business segments and geographies
- Understand the financial evolution of the company over the last five years
- Build the periodic assessment of the company's performance for five year adjusted financial data along with key ratios and market capitalization
Customers who bought this item also bought
Company Financials: Inspire Pharmaceuticals
Company Financials: ISTA Pharmaceuticals, Inc.
Company Financials: Jazz Pharmaceuticals, Inc.
Company Financials: Oncogenex Pharmaceuticals, Inc.
Company Financials: DUSA Pharmaceuticals, Inc.
Company Financials: Watson Pharmaceuticals, Inc.
Company Financials: POZEN, Inc.
Company Financials: Regeneron Pharmaceuticals, Inc.
Company Financials: Altus Pharmaceuticals Inc.
Company Financials: Idenix Pharmaceuticals, Inc.
|
|
|
|
